Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study

Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study

Background: Direct-acting antivirals (DAAs) are curative treatments for hepatitis C virus (HCV) infection, a condition affecting over 100,000 Ontarians. Although DAAs are covered under the public drug programs in Ontario, receiving prescriptions depends on access to healthcare. The aim of this study...

Full description

Bibliographic Details
Main Authors: Natalia Konstantelos, Ahmad Shakeri, Daniel McCormack, Anabel Campos-Meade, Tara Gomes, Michelle Murti, Valérie Pierre-Pierre, Mina Tadrous
Format: Article
Language:English
Published: Public Health Agency of Canada 2022-04-01
Series:Canada Communicable Disease Report
Subjects:
hepatitis c
direct-acting antivirals
access to medicine
health services research
Online Access:https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-4-april-2022/differences-hep-c-treatment-across-ontario.html

Internet

https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-4-april-2022/differences-hep-c-treatment-across-ontario.html

Similar Items